DE60136736D1 - Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose - Google Patents
Pyrimidinonderivate und deren verwendung bei der behandlung von atheroskleroseInfo
- Publication number
- DE60136736D1 DE60136736D1 DE60136736T DE60136736T DE60136736D1 DE 60136736 D1 DE60136736 D1 DE 60136736D1 DE 60136736 T DE60136736 T DE 60136736T DE 60136736 T DE60136736 T DE 60136736T DE 60136736 D1 DE60136736 D1 DE 60136736D1
- Authority
- DE
- Germany
- Prior art keywords
- atherosclerosis
- treatment
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024807.0A GB0024807D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
PCT/EP2001/011562 WO2002030911A1 (en) | 2000-10-10 | 2001-10-05 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60136736D1 true DE60136736D1 (de) | 2009-01-08 |
Family
ID=9901005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60136736T Expired - Lifetime DE60136736D1 (de) | 2000-10-10 | 2001-10-05 | Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose |
Country Status (11)
Country | Link |
---|---|
US (2) | US7169924B2 (de) |
EP (1) | EP1337517B1 (de) |
JP (1) | JP2004511473A (de) |
AR (1) | AR035068A1 (de) |
AT (1) | ATE415392T1 (de) |
AU (1) | AU2002223599A1 (de) |
CA (1) | CA2459746A1 (de) |
DE (1) | DE60136736D1 (de) |
ES (1) | ES2317949T3 (de) |
GB (1) | GB0024807D0 (de) |
WO (1) | WO2002030911A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001235466B2 (en) * | 2000-02-16 | 2004-04-22 | Glaxo Group Limited | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
EP1735457A4 (de) | 2004-04-16 | 2007-08-29 | Glaxo Group Ltd | VERFAHREN ZUR BESTIMMUNG VON Lp-PLA2-AKTIVITÄT UND HEMMUNG VON Lp-PLA2 AKTIVITÄT |
US20090062365A1 (en) * | 2005-12-23 | 2009-03-05 | Udo Bauer | Pyrazoles for the Treatment of GERD and IBS |
JP2010506852A (ja) * | 2006-10-13 | 2010-03-04 | グラクソ グループ リミテッド | 二環式ヘテロ芳香族化合物 |
US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
CA2687079A1 (en) * | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
KR101730290B1 (ko) * | 2007-05-11 | 2017-04-25 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
US9011821B2 (en) | 2010-06-18 | 2015-04-21 | Whitehead Institute For Biomedical Research | PLA2G16 as a target for antiviral compounds |
EP2649053B1 (de) | 2010-12-06 | 2015-11-04 | Glaxo Group Limited | Pyrimidinonverbindungen zur verwendung bei der behandlung von durch lp-pla2 bedingten krankheiten oder zuständen |
US20130267544A1 (en) | 2010-12-17 | 2013-10-10 | Peter Adamson | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases |
WO2012129792A1 (zh) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | 嘧啶酮类化合物、其制备方法及药物组合物和用途 |
EP2725024A4 (de) | 2011-06-27 | 2014-12-03 | Shanghai Inst Materia Medica | Heterocyclische azolverbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung und verwendung davon |
US9273054B2 (en) | 2011-07-27 | 2016-03-01 | Glaxo Group Limited | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors |
EP2739627A4 (de) | 2011-07-27 | 2015-01-21 | Glaxo Group Ltd | 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren |
FR2994184B1 (fr) * | 2012-08-02 | 2017-12-08 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
UY35276A (es) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad de Lp-PLA2 |
KR20150108896A (ko) | 2013-01-25 | 2015-09-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Lp-pla2의 억제제로서의 비시클릭 피리미돈 화합물 |
RU2015135806A (ru) | 2013-01-25 | 2017-03-03 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
AU2016275764B8 (en) | 2015-06-11 | 2021-03-04 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
CN111825695B (zh) * | 2019-04-15 | 2022-04-12 | 中国科学院上海药物研究所 | 噁唑烷酮类化合物、其制备方法、用途及其药物组合物 |
US11591840B1 (en) * | 2019-10-31 | 2023-02-28 | Andersen Corporation | Power window operators, windows and methods |
PE20230092A1 (es) | 2019-11-09 | 2023-01-16 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2203988T3 (es) | 1997-11-06 | 2004-04-16 | Smithkline Beecham Plc | Compuestos de pirimidinona y composiciones farmaceuticas que los contienen. |
AU2001235466B2 (en) * | 2000-02-16 | 2004-04-22 | Glaxo Group Limited | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
US6649610B1 (en) * | 2001-05-23 | 2003-11-18 | University Of Central Florida | 2-oxo-1, 4-benzoxazine compounds for treatment of tuberculosis |
-
2000
- 2000-10-10 GB GBGB0024807.0A patent/GB0024807D0/en not_active Ceased
-
2001
- 2001-10-05 AU AU2002223599A patent/AU2002223599A1/en not_active Abandoned
- 2001-10-05 DE DE60136736T patent/DE60136736D1/de not_active Expired - Lifetime
- 2001-10-05 AT AT01986682T patent/ATE415392T1/de not_active IP Right Cessation
- 2001-10-05 EP EP01986682A patent/EP1337517B1/de not_active Expired - Lifetime
- 2001-10-05 WO PCT/EP2001/011562 patent/WO2002030911A1/en active Application Filing
- 2001-10-05 US US10/398,977 patent/US7169924B2/en not_active Expired - Fee Related
- 2001-10-05 CA CA002459746A patent/CA2459746A1/en not_active Abandoned
- 2001-10-05 JP JP2002534297A patent/JP2004511473A/ja active Pending
- 2001-10-05 ES ES01986682T patent/ES2317949T3/es not_active Expired - Lifetime
- 2001-10-10 AR ARP010104761A patent/AR035068A1/es unknown
-
2006
- 2006-07-07 US US11/456,129 patent/US7462620B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1337517A1 (de) | 2003-08-27 |
US20060241126A1 (en) | 2006-10-26 |
AU2002223599A1 (en) | 2002-04-22 |
ATE415392T1 (de) | 2008-12-15 |
CA2459746A1 (en) | 2002-04-18 |
WO2002030911A1 (en) | 2002-04-18 |
US7169924B2 (en) | 2007-01-30 |
GB0024807D0 (en) | 2000-11-22 |
ES2317949T3 (es) | 2009-05-01 |
US7462620B2 (en) | 2008-12-09 |
US20040058941A1 (en) | 2004-03-25 |
EP1337517B1 (de) | 2008-11-26 |
JP2004511473A (ja) | 2004-04-15 |
AR035068A1 (es) | 2004-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60136736D1 (de) | Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose | |
ATE374204T1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
ATE309224T1 (de) | Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren | |
DE60133897D1 (de) | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren | |
DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
DE50009607D1 (de) | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung | |
DE60138768D1 (de) | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln | |
DE60112791D1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität | |
ATE375987T1 (de) | Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel | |
DE60017894D1 (de) | Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen | |
DE69925186D1 (de) | Anreichung von Glukosaminoglykanen und deren Vorstufen in Lebensmitteln | |
DE69826662D1 (de) | 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren | |
DE59903869D1 (de) | Verwendung von nanoskaligen sterolen und sterolestern | |
ATE384695T1 (de) | Carbamat caspase inhibitoren und deren verwendung | |
ATE375344T1 (de) | Azolotriazine und pyrimidine | |
DE60209486D1 (de) | Pyranoindazole und ihre verwendung in der glaukombehandlung | |
ATE348805T1 (de) | 2-acyl-indolderivate und deren verwendung als antitumormittel | |
DE60233265D1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
DK1212317T3 (da) | Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser | |
DE60010538D1 (de) | Kosmetische Tensid-Präparate und deren Verwendung | |
DE60001735D1 (de) | 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv | |
ATE293620T1 (de) | Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren | |
ATE300525T1 (de) | Uracilverbindungen und deren verwendung | |
DE69907802D1 (de) | Thermisch wirkende Pflaster und seiner Verwendung | |
DE60017133D1 (de) | Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |